Shares of Doximity, Inc. (NASDAQ:DOCS – Get Free Report) hit a new 52-week high on Wednesday after Baird R W upgraded the stock to a strong-buy rating. The company traded as high as $40.99 and last traded at $40.30, with a volume of 863782 shares changing hands. The stock had previously closed at $40.16.
Other equities analysts also recently issued reports about the stock. JPMorgan Chase & Co. raised their target price on shares of Doximity from $27.00 to $30.00 and gave the company a “neutral” rating in a report on Monday, August 19th. Truist Financial reissued a “hold” rating and set a $35.00 price objective (up from $31.00) on shares of Doximity in a research note on Wednesday, August 14th. Evercore ISI upped their target price on Doximity from $29.00 to $34.00 and gave the company an “in-line” rating in a research note on Friday, August 9th. Canaccord Genuity Group raised their price target on Doximity from $37.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, August 20th. Finally, Needham & Company LLC raised Doximity from a “hold” rating to a “buy” rating and set a $38.00 price target for the company in a report on Friday, August 9th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Doximity presently has an average rating of “Hold” and a consensus price target of $32.42.
Read Our Latest Research Report on Doximity
Insider Buying and Selling at Doximity
Institutional Trading of Doximity
Institutional investors and hedge funds have recently bought and sold shares of the business. Norges Bank acquired a new stake in shares of Doximity in the fourth quarter worth $35,995,000. Blair William & Co. IL raised its position in Doximity by 31.7% in the first quarter. Blair William & Co. IL now owns 90,600 shares of the company’s stock valued at $2,438,000 after purchasing an additional 21,787 shares during the period. Edmond DE Rothschild Holding S.A. raised its position in Doximity by 15.1% in the fourth quarter. Edmond DE Rothschild Holding S.A. now owns 2,302,240 shares of the company’s stock valued at $64,555,000 after purchasing an additional 301,290 shares during the period. Pinebridge Investments L.P. acquired a new position in shares of Doximity during the fourth quarter worth about $2,845,000. Finally, Acadian Asset Management LLC boosted its position in shares of Doximity by 128.7% in the first quarter. Acadian Asset Management LLC now owns 96,442 shares of the company’s stock worth $2,590,000 after buying an additional 54,281 shares during the period. Institutional investors and hedge funds own 87.19% of the company’s stock.
Doximity Stock Up 1.4 %
The firm has a market cap of $7.53 billion, a price-to-earnings ratio of 56.43, a price-to-earnings-growth ratio of 5.15 and a beta of 1.27. The business has a 50 day moving average price of $32.93 and a 200-day moving average price of $28.91.
Doximity (NASDAQ:DOCS – Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported $0.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.16 by $0.06. The company had revenue of $126.68 million during the quarter, compared to the consensus estimate of $119.88 million. Doximity had a net margin of 32.53% and a return on equity of 19.26%. Research analysts anticipate that Doximity, Inc. will post 0.8 earnings per share for the current fiscal year.
Doximity Company Profile
Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.
Featured Stories
- Five stocks we like better than Doximity
- What to Know About Investing in Penny Stocks
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- 3 Fintech Stocks With Good 2021 Prospects
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Receive News & Ratings for Doximity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Doximity and related companies with MarketBeat.com's FREE daily email newsletter.